These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34074111)

  • 1. [Perindopril: a long-term certainty in treating hypertension].
    Souček M
    Vnitr Lek; 2021; 67(2):119-124. PubMed ID: 34074111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.
    van Vark LC; Bertrand M; Akkerhuis KM; Brugts JJ; Fox K; Mourad JJ; Boersma E
    Eur Heart J; 2012 Aug; 33(16):2088-97. PubMed ID: 22511654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine.
    Borghi C; Morbini M; Cicero AF
    J Cardiovasc Med (Hagerstown); 2015 May; 16(5):390-9. PubMed ID: 25590639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity.
    Marre M; Leye A
    Diab Vasc Dis Res; 2007 Sep; 4(3):163-73. PubMed ID: 17907106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
    Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
    Ram CV
    Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS inhibitors' dose-dependent efficacy: myth or reality?
    Taddei S
    Curr Med Res Opin; 2015; 31(7):1245-56. PubMed ID: 25985327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
    Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M
    Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials.
    Brady AJ
    Clin Drug Investig; 2007; 27(3):149-61. PubMed ID: 17305412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases.
    Strauss MH; Hall AS; Narkiewicz K
    Cardiovasc Drugs Ther; 2023 Aug; 37(4):757-770. PubMed ID: 34533690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.